BioXcel Therapeutics - Chapter 11 Plan Terms

BioXcel’s liquidating Chapter 11 plan is premised on the sale of substantially all of its assets to a Teva affiliate for $57.5 million in cash plus up to $67.5 million in contingent milestone payments linked to FDA approval of its pending at-home IGALMI sNDA and future sales. Net of reserves for administrative and priority claims, professional fees, and the wind-down, proceeds are applied first to the up to $77.25 million DIP provided by Oaktree- and Qatar Investment Authority-affiliated lenders, which rolled up $58.25 million of their approximately $111.8 million in prepetition term loan principal, and then to their remaining prepetition secured claims, which are projected to recover 84.4%. General unsecured creditors will look primarily to a reserve funded with 30% of litigation recoveries, capped at $1 million, for a projected recovery of 0% to 2.9%.

Plan Terms

Overview

Teva Sale

Milestone Payments

DIP and Other Unclassified Claims

Treatment of Claims and Interests

GUC Recovery Reserve and Retained Causes of Action

Key Dates

Pending Matters

DIP Financing

Prepetition Capital Structure

Business and Path to Chapter 11

Liquidation Trust and Reserves

Releases, Exculpation and Injunction

Conditions to the Effective Date

Consent Rights and Plan Modifications

Other Plan Provisions